Literature DB >> 15613309

Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Francine Bouchonnet1, Elisabeth Dam, Fabrizio Mammano, Vaea de Soultrait, Gaëlle Henneré, Henri Benech, François Clavel, Allan J Hance.   

Abstract

Human immunodeficiency virus type I (HIV-1) reverse transcriptase (RT) resistance mutations reduce the susceptibility of the virus to nucleoside analogues but may also impair viral DNA synthesis. To further characterize the effect of nucleoside analogue resistance mutations on the efficiency and kinetics of HIV-1 DNA synthesis and to evaluate the impact of the depletion of deoxynucleoside triphosphates (dNTP) on this process, DNA synthesis was evaluated by allowing DNA synthesis to proceed with natural HIV-1 templates and primers, either within permeabilized viral particles or in newly infected cells, and quantifying the products by real-time PCR. Three recombinant viruses derived from three pNL4-3 molecular clones expressing mutations associated with resistance to zidovudine: a clone expressing RT mutation M184V, a clone expressing mutations M41L plus T215Y (M41L+T215Y), and clinical isolate BV34 (carrying seven resistance mutations). Following infection of P4 cells, the BV34 mutant, but not viruses expressing the M184V mutation or M41L+T215Y, exhibited a defect in DNA synthesis. Importantly, however, for mutants carrying the M184V mutation or M41L+T215Y mutations, a defect could be detected by using target cells in which dATP pools had been reduced by pretreatment with hydroxyurea. Based on these observations, we developed a recombinant-virus assay to assess the effects of hydroxyurea pretreatment on infectivity of viruses carrying plasma-derived RT sequences from patients with nucleoside resistance. Using this assay, we found that many, but not all, viruses carrying RT resistance mutations display an increased sensitivity to hydroxyurea, suggesting that the impact of RT resistance mutations on viral replication may be more profound in cell populations characterized by smaller dNTP pools.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15613309      PMCID: PMC538537          DOI: 10.1128/JVI.79.2.812-822.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies.

Authors:  E Race; E Dam; V Obry; S Paulous; F Clavel
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

2.  Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding.

Authors:  U O'Doherty; W J Swiggard; M H Malim
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.

Authors:  P R Harrigan; S Bloor; B A Larder
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.

Authors:  G Bleiber; M Munoz; A Ciuffi; P Meylan; A Telenti
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.

Authors:  P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.

Authors:  Bluma G Brenner; Jean-Pierre Routy; Marco Petrella; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Bonnie Spira; Vidal Essabag; Brian Conway; Richard Lalonde; Rafick-Pierre Sekaly; Mark A Wainberg
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.

Authors:  F Mammano; V Trouplin; V Zennou; F Clavel
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.

Authors:  T Imamichi; S C Berg; H Imamichi; J C Lopez; J A Metcalf; J Falloon; H C Lane
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.

Authors:  Jean-Luc Meynard; Muriel Vray; Laurence Morand-Joubert; Esther Race; Diane Descamps; Gilles Peytavin; Sophie Matheron; Claire Lamotte; Sonia Guiramand; Dominique Costagliola; Françoise Brun-Vézinet; François Clavel; Pierre-Marie Girard
Journal:  AIDS       Date:  2002-03-29       Impact factor: 4.177

10.  Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase.

Authors:  Koen K A Van Rompay; Tim B Matthews; Joanne Higgins; Don R Canfield; Ross P Tarara; Mark A Wainberg; Raymond F Schinazi; Niels C Pedersen; Thomas W North
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

View more
  6 in total

1.  Effect of cell cycle arrest on the activity of nucleoside analogues against human immunodeficiency virus type 1.

Authors:  Sebastien Wurtzer; Séverine Compain; Henri Benech; Allan J Hance; François Clavel
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

2.  Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B.

Authors:  Sebastien Wurtzer; Armelle Goubard; Fabrizio Mammano; Sentob Saragosti; Denise Lecossier; Allan J Hance; François Clavel
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

3.  Selection and characterization of Autographa californica multiple nucleopolyhedrovirus DNA polymerase mutations.

Authors:  Guozhong Feng; David K Thumbi; Jondavid de Jong; Jeffrey J Hodgson; Basil M Arif; Daniel Doucet; Peter J Krell
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

4.  Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.

Authors:  Danielle Perez-Bercoff; Sébastien Wurtzer; Séverine Compain; Henri Benech; François Clavel
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

5.  The emergence of HIV transmitted resistance in Botswana: "when will the WHO detection threshold be exceeded?".

Authors:  Raffaele Vardavas; Sally Blower
Journal:  PLoS One       Date:  2007-01-17       Impact factor: 3.240

6.  Delaying reverse transcription does not increase sensitivity of HIV-1 to human TRIM5α.

Authors:  Emilie Battivelli; Denise Lecossier; François Clavel; Allan J Hance
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.